Contingency management, often shortened to CM, is a behavioural treatment that uses planned positive reinforcement to support specific recovery goals. An agreed action, such as attending an appointment or providing a sample that meets a defined treatment target, is followed by an incentive under clear programme rules.
It is not a system for punishing people who struggle. A well-designed programme explains the goal, measurement, incentives and response to setbacks in advance. Essential healthcare, dignity and basic needs should not depend on earning a reward. CM is best understood as one component of care rather than a complete answer to every substance-use problem.
How does contingency management work?
The basic principle is to make a helpful behaviour more immediately rewarding. Longer-term benefits of recovery may feel distant, while the effects or relief associated with substance use can be immediate. CM introduces a planned positive consequence for an agreed behaviour within treatment.
The VA describes programmes using incentives linked to objectively assessed recovery behaviours, including substance-use targets. Timing, consistency and a clearly defined protocol matter. An informal promise of a reward at some future point is not automatically equivalent to a researched CM intervention. VA: contingency management in evidence-based treatment.
What happens in a programme?
Before starting, the service should explain what behaviour is being reinforced and how it will be assessed. A target needs to be specific enough that both you and the clinician understand it. Attendance, medication-related engagement and verified changes in substance use are different targets; evidence for one cannot simply be assumed to apply to another.
You should receive a clear explanation of when incentives are available, how they are provided and whether the schedule changes over time. Ask what happens after a missed appointment, an inconclusive result or a result that does not meet the target. These rules should not be invented retrospectively or depend on whether a staff member approves of you.
Testing needs appropriate clinical interpretation. Ask what a test can show, what its limits are and how prescribed medicines or unexpected findings are considered. There should be a fair process for discussing disputed results. A laboratory result is clinical information, not a moral judgement.
A practical example
Imagine a programme that reinforces attendance at agreed treatment appointments. The target, recording process and incentive schedule are explained beforehand. When an appointment is attended, the agreed reinforcement follows promptly. Meanwhile, therapy addresses coping skills, health concerns and practical barriers.
If an appointment is missed because transport fails, the useful response includes understanding that obstacle. The programme can maintain its transparent rules while helping solve the access problem. Calling the person unmotivated or withholding necessary treatment would not address why attendance became difficult.
This is an illustration of the structure, not a template for an individual programme. Clinical protocols, eligibility and funding arrangements vary, and a service must check the requirements that apply where it operates.
What does the evidence show?
The ASAM and AAAP clinical guideline identifies CM as a central evidence-based treatment for stimulant-use disorder. The guideline also emphasises assessment of medical and psychiatric complications and the need for an appropriate level of care. Incentives should not distract from those wider clinical responsibilities. ASAM/AAAP guideline summary hosted by the CDC.
In a randomised study involving 77 people receiving methadone treatment who also used cocaine, adding a prize-based CM procedure improved cocaine-negative samples and group attendance during treatment. This demonstrates a role alongside existing care, not that incentives should replace opioid-use medication. Read the original community-clinic trial.
Research also examines specific programme designs. A study comparing gambling behaviour in participants receiving prize-based CM or standard care did not find increased gambling in the CM group. That finding concerns the tested procedure and population; individual concerns about gambling or incentives should still be assessed rather than dismissed. Research on prize-based CM and gambling.
Why programme design matters
The size, timing and consistency of reinforcement are part of the intervention, not incidental details. Ask whether the service uses a defined protocol and how staff are trained to deliver it. A programme that changes the target frequently or provides incentives unpredictably may differ substantially from the treatment described in research.
Also ask how the programme measures outcomes beyond the immediate target. More attended appointments can be valuable, but attendance alone does not establish that symptoms, safety or functioning have improved. A clinically useful review considers the person’s broader goals and whether the rest of the care plan is effective.
CM alongside other treatments
Community reinforcement helps build a more rewarding daily life and may be combined with CM. CBT and relapse-prevention work can develop skills for responding to triggers and setbacks. These approaches have different roles even when delivered within one programme.
For opioid-use disorder, indicated medication remains a separate clinical consideration. An incentive scheme should not become a condition for receiving essential treatment or a reason to stop prescribed medication. The medications guide explains that part of care.
People using stimulants may also need assessment of sleep, mood, psychosis, physical health and other substances. Our stimulant-use treatment guide and cocaine treatment guide place behavioural treatments within that broader picture.
Consent, privacy and fairness
Participation should be based on an understandable agreement. Ask what information is collected, who sees it and whether results are shared outside the treatment team. Remote testing or digital rewards can create additional privacy questions, including what an app records and what appears in notifications or payment records.
Practical fairness matters too. A programme should consider transport, disability, work, caring commitments and access to technology. Transparent rules are important, but they do not remove the responsibility to recognise barriers. Discuss whether reasonable adaptations are possible and whether an alternative treatment format would be more accessible.
Rewards should not be tied to unrelated personal disclosures or compliance with a clinician’s preferences. Nor should food, housing, emergency care or necessary medication be withheld as leverage. A professional service should explain how it protects autonomy while delivering the intervention consistently.
What happens after incentives end?
Ask about the transition before the programme begins. The plan should consider what will support recovery when the formal rewards stop: meaningful activities, coping skills, relationships, medical care and access to further help. CM can support engagement, but the person’s life outside appointments still needs attention.
A review can identify what changed during the programme and which difficulties remain. Continued use or a return to use should prompt assessment and support, not a conclusion that treatment was wasted. A service should have a route for adjusting care without requiring the person to hide setbacks to preserve access.
Frequently asked questions
Is contingency management just paying people to stop using drugs?
That description misses the clinical structure. CM links planned reinforcement to a specific, measured treatment target under transparent rules. The protocol, assessment and wider care matter. It should not be reduced to an improvised offer of money or treated as a substitute for all other treatment.
What kinds of incentives are used?
Research and services have used different formats, including vouchers and prize-based systems. The appropriate design depends on the protocol and applicable rules. Ask what is offered, how it is funded and whether the terms are available in writing before you decide to participate.
What happens after a positive or unexpected test?
The service should explain this in advance. A result may affect the incentive schedule, but it should also lead to appropriate clinical review and support. Unexpected findings need interpretation. A missed target should not justify humiliation, abandonment or loss of necessary healthcare.
Does CM replace counselling?
Not necessarily. It can be combined with counselling, skills-based treatment and practical support. The important question is whether the programme addresses your actual needs. Earning incentives does not by itself resolve every reason for using substances or every difficulty associated with recovery.
Is it relevant for stimulant-use disorder?
Yes, major clinical guidance identifies an important role for CM in stimulant treatment. The assessment must still consider medical and psychiatric needs. Acute complications require appropriate care rather than waiting for the next behavioural-treatment appointment.
Can someone receiving opioid medication participate?
CM has been studied alongside medication treatment, including in people with co-occurring stimulant use. The clinician should explain the specific target and how care is coordinated. Medication should not be stopped or withheld merely because a person does not meet an incentive target.
What should I ask about a digital programme?
Ask how identity and results are checked, who can access the data and what happens if technology fails. Clarify device costs, privacy at home and the route to a real clinician. A digital platform does not remove the need for clinical assessment or support.
How long does treatment last?
Duration depends on the protocol and care plan. Ask about review points and the transition after incentives end. A study’s treatment period is not a guarantee of recovery by that date, and ongoing medical or psychological care may remain appropriate.
Discussing the right level of care
An initial assessment can clarify the substance-use pattern, health needs and available treatment options. Suspected overdose, severe intoxication or immediate danger requires urgent local help. A routine incentive programme is not an emergency response.
Sources and further reading
- ASAM/AAAP clinical practice guideline on stimulant-use disorder.
- VA: contingency management and related treatments.
- Randomised trial of CM alongside methadone treatment.
- Study of prize-based CM and gambling outcomes.
Related conditions and concerns
These links explain the wider care context. They are not a recommendation that this approach is suitable for everyone with the condition. Use the condition treatment guide to understand alternatives and the role of clinical assessment.